Retatrutide is a new pharmaceutical in the fight against obesity. This revolutionary drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By stimulating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately leads to significant reduction in body mass. While